Head-to-head evidence
AZD9550 vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
AZD9550
Developed by AstraZeneca
NCT06862791 · Phase 2 · completed
The study uses randomization, quadruple blinding, multiple placebo-controlled treatment groups, and includes 377 participants. Its primary endpoints are clinical weight-loss measures, but the results and whether the primary comparisons were met are not yet available, so the evidence cannot be rated as strong.
Next expected readout: October 2026 · NCT07017179 (registry estimate)
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06077864 · Phase 3 · completed
The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.
Next expected readout: December 2026 · NCT07768813 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD9550's landscape · survodutide's landscape